Head and Neck Squamous Cell Carcinoma
Research activity is centred on head and neck squamous cell carcinoma, including locally advanced, recurrent, and metastatic disease across the oral cavity, oropharynx, hypopharynx, and larynx.
- Locally advanced squamous cell carcinoma
- Recurrent or metastatic squamous cell carcinoma
- Untreated head and neck cancer
The portfolio also includes disease settings defined by platinum-refractory relapse and PD-L1-positive recurrent disease.
Radiotherapy and Chemoradiotherapy
Multiple studies focus on radiotherapy combined with systemic treatment in the management of head and neck cancers, with attention to both definitive and postoperative settings.
- Cetuximab-radiotherapy
- Cisplatin-radiotherapy
- Adjuvant chemoradiotherapy
These research areas include local control, survival outcomes, and preservation of function in tumours of the upper aerodigestive tract.
Immunotherapy and Immune Checkpoint Targeting
The sponsor supports trials involving immune checkpoint inhibitors and related combinations in head and neck oncology, particularly in settings where conventional treatment options remain limited.
- Nivolumab
- Durvalumab
- Avelumab
Interest extends to combinations with EGFR-targeted therapy, anti-PD-1 therapy, and other immuno-oncology approaches.
Salivary Gland and Sinonasal Tumours
Trials also address rarer head and neck malignancies, including carcinomas of the major salivary glands and tumours arising in the sinuses, with both resected and non-operable disease represented.
- Major salivary gland carcinoma
- Sinonasal malignancy
- Adenoid cystic carcinoma of the head and neck
Research in these areas includes radiation-based treatment and systemic combinations for uncommon tumour subtypes.
Organ Preservation and Functional Outcomes
Several studies are directed toward laryngeal preservation and the maintenance of swallowing and speech-related function during treatment of head and neck cancer.
- Laryngeal preservation
- Pharyngoesophageal function
- Cervical control
This area reflects interest in balancing tumour control with preservation of quality of life in cancers affecting the larynx and adjacent structures.
